# Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients

> **NCT02064569** · PHASE1,PHASE2 · COMPLETED · sponsor: **GenSight Biologics** · enrollment: 19 (actual)

## Conditions studied

- Leber Hereditary Optic Neuropathy

## Interventions

- **GENETIC:** GS010

## Key facts

- **NCT ID:** NCT02064569
- **Lead sponsor:** GenSight Biologics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-13
- **Primary completion:** 2020-06-25
- **Final completion:** 2020-06-25
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02064569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02064569, "Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02064569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*